SANUWAVE Health, Inc. (SNWV)
| Previous close | 0.0239 |
| Open | 0.0238 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0238 - 0.0238 |
| 52-week range | 0.0046 - 0.0300 |
| Volume | |
| Avg. volume | 333,666 |
| Market cap | 27.145M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history. Q1 2024 revenue increased between 51% and 56% compared to Q1 2023. UltraMist revenues for Q1 2024 increased by more than 55% versus Q1 2023 and accounted for approximately 95% of the Company’s total revenues. UltraMist applicator sales were an all time quarterly record and exceeded 65% of total revenues. EDEN
- GlobeNewswire
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer
Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE EDEN PRAIRIE, MN, April 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Peter Sorensen as its new CFO. Sorensen brings deep experience in finance, fore
- GlobeNewswire
SANUWAVE Announces Record Q4 and FY2023 Revenue
Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023 EDEN PRAIRIE, MN, March 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (the "Company" or "SAN
